Channel Expansion The acquisition by Elekta provides access to a broader global sales and service network for rapid uptake of Xoft's isotope-free system, enabling cross-sell to existing brachytherapy customers and integration into Elekta's oncology portfolio.

Shield-Free Market Xoft’s compact, isotope-free design eliminates the need for shielded rooms, opening sales opportunities at ambulatory surgical centers, community hospitals and private clinics worldwide for intraoperative radiation therapy and APBI.

Breast Cancer Focus Position Xoft as a convenient, single-session alternative for breast-conserving therapy, targeting surgical oncologists and radiation oncologists in centers performing APBI or IORT as part of breast cancer treatment programs.

Regulatory Ease Market the isotope-free technology as reducing regulatory hurdles, shielding requirements and shielding-related capital costs, appealing to procurement teams seeking faster deployment.

Evidence Based Leverage the ongoing post-market safety/efficacy study to generate real-world outcomes data to support reimbursement, clinician adoption, and expansion into new cancer sites such as brain tumors and gynecologic cancers.